What Полидан Treats: Main Uses and Benefits

The primary role of Полидан (Nucleospermate Sodium) is to offer comprehensive supportive therapeutic benefit in clinical situations where the body’s intrinsic defense and repair mechanisms may be under significant strain. Its classification as an immunomodulator and regenerative agent places its application within therapeutic strategies aimed at systemic support, a domain relevant for symptomatic management in contexts involving systemic imbalance.

The medication is generally considered relevant for easing the symptomatic burden associated with conditions like leukopenia, recurrent or protracted infections, and states of prolonged convalescence or compromised tissue restoration.

Supportive Care for Hematological Deficits

The medication is commonly used across conditions generally characterized by systemic imbalance and immunosuppression. It is applied in clinical settings marked by heightened physiological stress, notably in patients undergoing radiation therapy or intensive chemotherapy. This use provides support that helps ease the overall symptom burden of associated deficits, and may assist with managing symptoms related to blood cell count fluctuations.

Enhancing Biological Repair and Systemic Recovery

Полидан is relevant in contexts involving compromised tissue restoration and prolonged convalescence. It is applied in cases where symptoms cluster into patterns requiring supportive management, such as asthenia (persistent fatigue) following a major systemic illness or surgery, or non-healing wounds. This generally offers symptomatic relief that helps patients cope more steadily with difficult episodes, and contributes to maintaining a sense of stability and supports general well-being during symptomatic phases.

Quick Fact: Supportive Management for Persistent Fatigue
Polidan is commonly used to help manage the symptom of persistent fatigue that often accompanies a major systemic illness or is present during a delayed recovery phase.

The official regulatory profile for Полидан (Nucleospermate Sodium) strictly defines which population groups are permitted or prohibited from using the medicine. Use is generally established for adults (18 years and older) who do not possess any documented contraindications. The official label mandates that the medicine must not be used in cases of hypersensitivity to the drug or its components.

Absolute Contraindications

The following physiological states and age groups are explicitly contraindicated:

Category	Regulatory Status
Reproductive Status	Prohibited during Pregnancy and Lactation
Age Restriction	Prohibited for children under 3 years of age

Furthermore, use is strictly prohibited in patients with acute diseases of the liver, kidneys, pancreas, or gastrointestinal tract. This prohibition also extends to patients with decompensated chronic heart failure or cerebral circulatory disorders. The official regulatory instructions define a restricted eligibility status for individuals with malignant or pre-tumorous diseases of the lymphoid or myeloid tissue, requiring the medicine to be used only with special caution.

Interactions with other medicines and products — Official Regulatory Information for Полидан (Nucleospermate Sodium)

The interaction profile for Polidan, which contains Nucleospermate Sodium, is defined by specific pharmacodynamic effects and explicit statements of compatibility found in regulatory documentation. The product's official information does not list any mandatory timing separation requirements, pharmacokinetic interactions involving CYP enzymes or transporters, or restrictions related to food, alcohol, or herbal products.

Interaction Scope

Property	Value (Strictly Regulatory-Based)
Medicinal product categories with documented interactions	Anticoagulants, Cytostatics, Local Anesthetics
Specific interacting medicines (if explicitly listed)	Lidocaine
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic potentiation (Anticoagulants); Compatibility (Cytostatics and Lidocaine)
Timing-based interaction rules (if applicable)	None documented.
Population-specific interaction notes (if applicable)	None documented.
Interaction-related restrictions	Required caution due to enhanced effect with anticoagulants.

Interaction Classifications (High-Level)

Property	Value (Strictly Regulatory-Based)
Interaction severity classification	Use with caution (Pharmacodynamic potentiation); Permitted (Compatibility)
Interaction-context constraints	Co-administration is permitted for cytostatics and Lidocaine; Co-administration with anticoagulants requires attention to the enhanced effect.

Resulting Interaction Structure

Official interaction statements:

• Co-administration with anticoagulants is officially documented to enhance the action of the anticoagulant.
• The product can be used simultaneously with cytostatics, confirming permitted co-administration.
• The medicine can be used simultaneously with Lidocaine, formally stating compatibility.

The regulatory profile strictly outlines the identified pharmacodynamic potentiation risk with anticoagulants and formally declares compatibility with both cytostatics and Lidocaine. This structure governs the constraints for co-administration but lacks documented metabolic or timing-based interaction rules.

Molecular Target and Inhibition

Полидан acts as an inhibitor of the protein-tyrosine kinase Src. The inhibition is achieved through competitive binding at the ATP-binding site within the kinase domain. This interaction prevents the phosphorylation and subsequent activation of the Src enzyme. The targeted action occurs selectively in bone tissue, specifically within osteoclasts.

Intracellular Mechanism in Osteoclasts

Src kinase is a critical intracellular mediator in osteoclasts, which are the cells responsible for bone resorption. Upon activation, Src initiates the cytoskeletal organization required for the cell to attach to the bone surface. Inhibition by Полидан disrupts the formation of the osteoclast's specialized structures—the sealing zone and the ruffled border. This action directly reduces the functional capability and efficiency of osteoclasts.

Influence on Bone Remodeling Dynamics

The resulting decrease in osteoclast function leads to reduced bone resorption. This molecular modulation restricts the activation of downstream signaling factors, thereby influencing the dynamic balance between bone formation and bone resorption within the skeletal system. The biological target is a key regulator of overall bone remodeling activity.

The administration of Nucleospermate Sodium (Полидан) is governed by specific parameters regarding the route, dose, and timing of application. The medicine is indicated for use via subcutaneous (SC), intramuscular (IM), and rectal routes. The standard product for injection is provided as a 15 mg/mL solution.

---

Standard Regimen and Frequency

For adult patients, the standard single dose is 75 mg (5 mL) for prophylactic use, administered once daily. For therapeutic purposes, the dose range extends up to a maximum daily dose of 150 mg (10 mL). While a daily regimen is common, a treatment course may also consist of a single injection repeated after an interval of 72 hours (3–7 days), with the total prophylactic course duration typically lasting 3 to 5 days.

---

Preparation and Contextual Timing

Strict adherence to preparation and administration technique is required. The solution must be warmed to body temperature prior to use. For intramuscular injection, it is permitted to combine the solution with 0.5 mL of 0.5% or 2% Lidocaine solution. The injection itself must be administered slowly, over 1.5 to 2 minutes.

A critical constraint for prophylactic use involves timing relative to systemic therapies: the dose is administered 24 hours before the start of a treatment or 24 hours after its conclusion. Pediatric dosing for children over three years old is calculated based on body surface area (BSA) at 42 mg/m² per day, with a maximum single dose of 75 mg (5 mL).

Полидан: Recent Clinical Evidence

Research on Полидан (Polydan), which contains the active compound polydeoxyribonucleotide (PDRN), primarily involves its evaluation in conditions related to tissue damage and inflammation, such as osteoarthritis (OA) and certain pain syndromes.

Core Research Areas

Studies have focused on the potential effects of PDRN when administered via intra-articular injection (into a joint space), particularly for knee OA. This research has often sought to compare the substance's effect on pain and function against other commonly used treatments, such as hyaluronic acid (HA).

Research Focus	Study Design Example
Knee Osteoarthritis Pain	Randomized Controlled Trials (RCTs) comparing PDRN to HA or placebo.
Pain Intensity	Meta-analyses assessing changes in Visual Analogue Scale (VAS) scores.
Functional Outcomes	Evaluation of scores like the Knee Injury and Osteoarthritis Outcome Score (KOOS).

Key Findings on Pain and Function

A systematic review and meta-analysis of five RCTs involving intra-articular PDRN for knee OA reported differences in pain intensity compared to HA injections. The analysis indicated that the PDRN group showed greater reported improvement in pain after one and two months post-injection. However, this reported difference was generally not sustained at the four-month follow-up.

Regarding functional status (e.g., joint mobility or stiffness), the pooled data from these studies generally did not find significant differences between PDRN and HA at any time point assessed. The substance has also been investigated in other contexts, including various forms of chronic pain, with observational studies reporting positive changes in pain severity scores for participants unable to fully control their pain with standard therapies. Further, larger-scale research is warranted to clarify its long-term activity, safety profile, and role in specific treatment protocols.

Key Studies & References Effectiveness and safety of intra-articular polydeoxyribonucleotide (PDRN) versus hyaluronic acid (HA) in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials

Common questions about Полидан (FAQ)

Q: How does the purpose of Полидан differ from common over-the-counter supplements?

According to official product information, Polidan is classified as a prescription medicine: an immunomodulator and a hematopoietic stimulator. This means it is specifically designed to influence the production of blood cells, such as neutrophils, and stimulate the body's cellular and humoral immunity. This targeted, pharmacological action sets it apart from general over-the-counter nutritional supplements.

Q: What are the most commonly reported non-serious side effects associated with Полидан?

Official regulatory documents describe several adverse reactions, although they do not always provide explicit frequency rankings. The most commonly noted non-serious effects include localized reactions at the injection site, such as pain, irritation, or redness. Other documented general effects include mild symptoms like headache, dizziness, and dry mouth.

Q: What factors might contribute to a person feeling like Полидан is not working for them?

The official label notes that the expected therapeutic effect, which involves the restoration of blood indicators, is generally observed within a window of 3 to 10 days of starting treatment. Therefore, the timeline for the drug's pharmacological action must be considered when evaluating the effects.

Q: Is there a patient information leaflet (PIL) or consumer medical information (CMI) that is easy to find online?

Official drug instructions and information for consumers, which are the equivalents of a Patient Information Leaflet (PIL) or Consumer Medical Information (CMI), are generally maintained online. This official documentation can typically be found on national drug register websites or through large, authorized online pharmaceutical resources.

Q: Is there a specific mechanism of action for Полидан that is easy for a layperson to understand?

According to official clinical pharmacology data, the medicine is described as a biogenic stimulator that affects proliferating cells in the body. Its main role is acting as an immunomodulator to stimulate the formation of blood cells, a process called hematopoiesis, and to support both cellular and humoral immunity (the body's natural defense systems).

Q: Does official information describe Полидан as being used for short-term problems or long-term management?

Official instructions define the use of Polidan for both short and potentially long-term administration. The injection form is typically used for short prophylactic and therapeutic courses lasting between 3 and 10 days. However, the rectal administration route has defined regimens that can extend up to 6 months.

Q: How long does it typically take for a person to begin feeling the expected effects of Полидан?

The official pharmacodynamics section states that the expected therapeutic effect, specifically the restoration of certain blood indicators, is generally observed within 3 to 10 days after initiating the treatment course.

Q: Is there a known duration after which the peak effect of Полидан occurs?

Official pharmacokinetic data is available for the injection forms of the medicine. Following a subcutaneous or intramuscular injection, the drug reaches its highest concentration in the blood, known as the T max, in approximately 0.5 hours (30 minutes).

Q: Do the effects of Полидан last for a specific, measurable amount of time?

The body's processing of the drug is described by its elimination half-life (T1/2), which is officially noted as approximately 60 hours. Furthermore, regulatory documents state that the drug's specific colony-stimulating effect on bone marrow is maintained for at least 72 hours.

Q: Is it possible for the body to develop a functional tolerance to Полидан over an extended period?

Regulatory pharmacokinetic information notes that when the injection is administered daily, an accumulation in the blood and bone marrow is observed only after the first four doses. This fact about accumulation is noted in official information regarding the drug's internal behavior.

Official Storage and Disposal Requirements

The medicine Полидан (Nucleospermate Sodium) must be stored and handled according to specific regulatory requirements to ensure its stability.

Storage Requirement	Official Condition
Temperature	Store between 4 C to 8 C (refrigerated).
Protection	Keep in a dry place and protected from light.
Handling Rules	Do not freeze and do not heat above 45 C.
Child Safety	Keep out of the sight and reach of children.

The official shelf-life for the unopened product is 3 years. The preservative-free injection solution must be used immediately after opening the vial; it must not be administered if sediment is present. All unused or expired product must be discarded in compliance with local and national regulations for pharmaceutical waste.